Disclosed herein are erasable label systems that involve nanocage molecules positioned around nanoparticles, which can be loaded with, bound to, or adsorbed with imaging agents. The nanocages can contain targeting arms composed of ssDNA or ssRNA that can be used to target biomolecules. For DNA or RNA targeting, this can be done directly. Antibodies can be targeted using avidin-biotin coupling to ssDNA or direct ssDNA conjugation to the antibody surface. ssDNA or ssRNA complementary to one of the arms can then be used to “erase” the label.

A method of determining the presence or absence of an antibody in a sample, the method comprising the steps of: (a) contacting the sample with a lysis composition comprising: (i) a quaternary ammonium compound; and (ii) a non-ionic surfactant; and (b) contacting the sample and the lysis composition with an antibody detection device.

Disclosed is a method of measuring the prostaglandin E main urinary metabolite (PGE-MUM), in which a mixture solution of a urine sample treated with alkali can directly be subjected to an antigen-antibody reaction system in an immunoassay of PGE-MUM, without neutralization and dilution followed by dispensation. The method of measuring PGE-MUM includes the steps of: a) mixing a urine sample with an alkaline aqueous solution, and b) subjecting the mixture solution resulting from a) to an immunoassay using a bicyclo PGE-MUM-immobilized or anti-bicyclo PGE-MUM antibody-immobilized solid phase to measure PGE-MUM in the urine sample, wherein the immunoassay is performed in a weakly-acidic basal buffer solution in the presence of a second pH buffering agent which exerts a buffering effect in the basic range and is different from the pH buffering agent contained in the basal buffer solution, and in the presence of a cationic surfactant.

We describe assay modules (e.g., assay plates, cartridges, multi-well assay plates, reaction vessels, etc.), processes for their preparation, and method of their use for conducting assays. Reagents may be present in free form or supported on solid phases including the surfaces of compartments (e.g., chambers, channels, flow cells, wells, etc.) in the assay modules or the surface of colloids, beads, or other particulate supports. In particular, dry reagents can be incorporated into the compartments of these assay modules and reconstituted prior to their use in accordance with the assay methods. A desiccant material may be used to maintain and stabilize these reagents in a dry state.

A diagnostic test system includes a housing, a reader, and a data analyzer. The housing includes a port constructed and arranged to receive a test strip that includes a flow path for a fluid sample, a sample receiving zone couple to the flow path, a label that specifically binds a target analyte, a detection zone coupled to the flow path and comprising a test region exposed for optical inspection and having an immobilized test reagent that specifically binds the target analyte, and at least one reference feature. The reader is operable to obtain light intensity measurements from exposed regions of the test strip when the test strip is loaded in the port. The data analyzer is operable to perform operations including at least one of (a) identifying ones of the light intensity measurements obtained from the test region based on at least one measurement obtained from the at least one reference feature, and (b) generating a control signal modifying at least one operational parameter of the reader based on at least one measurement obtained from the at least one reference feature.

According to one embodiment of the present application, a biosensor, the biosensor comprising: a reaction part including a magnetic nanoparticle complex, a first electrode, and a second electrode; and a sample introduction part forming a passage so that a sample can be introduced into the reaction part from an outside of the biosensor; wherein the magnetic nanoparticle complex includes a first capturing substance for capturing a first target substance, a magnetic nanoparticle, and a reaction substance that performs at least one of an oxidation reaction and a reduction reaction, wherein the magnetic nanoparticle complex is magnetic in the reaction part, and has a property that mobility can be changed according to a change in a condition of the reaction part, wherein the first electrode, a second capturing substance for capturing a second target substance is fixed, wherein the second electrode is an electrode different from the first electrode, and characterized in that at least one of the first target substance and the second target substance is included in the sample, may be provided.

The present invention relates to a peptide capable of binding to rheumatoid arthritis autoantibodies, which is a consecutive 10-25 amino acid sequence of any one fragment of the group consisting of SEQ ID NO: 3-4, 7-13 or 16-19, wherein the peptide fragment has an epitope that binds to the rheumatoid arthritis autoantibodies. Furthermore, the peptide fragment bound to the rheumatoid arthritis autoantibodies is used for testing rheumatoid arthritis, and according to this use, the present invention provides a method for testing rheumatoid arthritis disease and a test reagent kit used for determining whether a subject to be tested suffers from rheumatoid arthritis disease.

Enantiomeric pairs of molecular wires comprised of oligomeric nucleic acids, wherein the oligomers of each wire possess identical nucleobase pair sequences and thus identical conductivity as between wires, are constructed and used to sense biological or chemical entities of interest at the cellular or molecular level. The oligomeric molecular wires conduct voltage inputs to sensing subsystem integrated circuitry, either from an electrostatic potential arising from a targeting agent (i.e., a capture agent) binding to an intended biological or chemical target molecule, or from an electrostatic potential associated with a reference molecule that has non-specific interactions with the environment. The chirality of the oligomers imparts selectivity to either the targeting agent or the reference molecule during assembly of the sensing subsystem.

Provided is at least one method of suppressing, in an immunoassay using surface plasmon-field enhanced fluorescence spectroscopy (SPFS), nonspecific signals generated by nonspecific adsorption of contaminants contained in a sample to an SPFS sensor section (e.g., a primary antibody, a solid-phase layer and a metal thin film). At least one method relates to a method of suppressing nonspecific signals originating from contaminants in an immunoassay using surface plasmon-field enhanced fluorescence spectroscopy (SPFS) (including cases where a receptor for a compound to be measured is used in place of a primary antibody), the method comprising performing at least one pretreatment.

An immunoassay cartridge is disclosed that can enhance the reliability of an antigen-antibody reaction while increasing a speed of an antigen-antibody reaction. An immunoassay cartridge includes a reaction chamber and a fluorescence sensor assembly. A plurality of antibodies or antigens is attached to an inner surface including a bottom surface of the reaction chamber closest to the sensor. The fluorescence sensor assembly is disposed on a bottom surface of the reaction chamber. Since the bottom surface of the reaction chamber and the upper surface of the fluorescence sensor assembly are arranged to coincide with each other, even if fluid is repeatedly moved in a first direction after the fluid moves in a second direction in the reaction chamber and then moved in the first direction, there is no obstacle in the movement of the fluid. Thus, it is possible to increase the probability of antigen-antibody reaction in the reaction chamber.